ImmunityBio (IBRX) Skyrockets as Anktiva Propels 671% Revenue Jump [Yahoo! Finance]
ImmunityBio, Inc. (IBRX)
Company Research
Source: Yahoo! Finance
We recently published 10 Stocks Winning the Market . ImmunityBio Inc. (NASDAQ:IBRX) was one of the best performers on Tuesday. ImmunityBio rallied for a sixth consecutive day on Tuesday to hit a nearly five-year high, as investors continued to load portfolios, thanks to a 671 percent revenue expansion last year driven by its bladder cancer treatment, Anktiva. At intra-day trading, the stock surged to its highest price of $12.28 before paring gains to finish the session just up by 17.50 percent at $11.55 apiece. In an updated report, ImmunityBio Inc. (NASDAQ:IBRX) said that it incurred total revenues of $113 million last year, marking a 671 percent expansion from only $14.7 million in 2024, with net product revenues alone soaring by 700 percent, thanks to a 750 percent sales volume expansion from Anktiva. ImmunityBio (IBRX) Skyrockets as Anktiva Propels 671% Revenue Jump 15 States with the Best Healthcare in the US However, ImmunityBio Inc. (NASDAQ:IBRX) remained at a net
Show less
Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026 [Yahoo! Finance]Yahoo! Finance
- ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026Business Wire
- Assessing ImmunityBio (IBRX) Valuation After Trial Progress And Strong Anktiva Commercial Momentum [Yahoo! Finance]Yahoo! Finance
- Is It Too Late To Consider ImmunityBio (IBRX) After The Recent Share Price Surge? [Yahoo! Finance]Yahoo! Finance
- SHINE Raises $240 Million in Funding to Advance Commercial Fusion Technology [Yahoo! Finance]Yahoo! Finance
IBRX
Earnings
- 5/12/25 - Miss
IBRX
Sec Filings
- 2/26/26 - Form 4
- 2/25/26 - Form SCHEDULE
- 2/24/26 - Form 4
- IBRX's page on the SEC website